Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Minimal long-term cardiac safety findings were reported with ozanimod treatment in patients with ...

Please provide your email address to receive an email when new articles are posted on . Zeposia demonstrated a low incidence of treatment-related cardiac adverse events for patients with ulcerative ...

Acalabrutinib demonstrates a favorable cardiovascular safety profile in CLL, with low cardiac failure rates compared to ibrutinib and chemoimmunotherapy. The selectivity of acalabrutinib reduces ...